Intellia Therapeutics (NTLA) Gains from Investment Securities (2022 - 2023)
Intellia Therapeutics (NTLA) posted quarterly Gains from Investment Securities of $100000.0 for Q1 2023, down 76.25% year-over-year from $421000.0 in Q1 2022, and down 98.16% quarter-over-quarter from $5.4 million in Q4 2022.
Powered by 
Analysis
Intellia Therapeutics (NTLA) Gains from Investment Securities (2022 - 2023) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Gains from Investment Securities for 2 consecutive years, with $100000.0 the latest figure, recorded in Q1 2023.
- In Q1 2023, Gains from Investment Securities fell 76.25% year-over-year to $100000.0; the TTM figure through Dec 2023 stood at $100000.0 (down 99.26% YoY), while the FY2023 annual figure was $100000.0, down 99.26% from the prior year.
- Gains from Investment Securities slipped to $100000.0 in Q1 2023 per NTLA's latest filing, from $5.4 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $7.8 million in Q3 2022 and bottomed at -$172000.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Intellia Therapeutics | 1.70 Bn | 1.70 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 100,000.00 |
| Dec 31, 2022 | 5.43 Mn |
| Sep 30, 2022 | 7.81 Mn |
| Jun 30, 2022 | -172,000.00 |
| Mar 31, 2022 | 421,000.00 |